skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Liposomal Eribulin Mesylate (Code C111899)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Liposomal Eribulin Mesylate

Definition: A liposome-encapsulated formulation of the mesylate salt form of eribulin, a synthetic, macrocyclic ketone analogue of halichondrin B, a substance derived from the marine sponge genus Halichondria, with potential antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits both the polymerization of tubulin and the assembly of microtubules. This results in the inhibition of mitotic spindle assembly, the induction of cell cycle arrest at G2/M phase, as well as tumor cell apoptosis. Compared to the administration of eribulin alone, liposomal delivery of eribulin allows for a longer half-life, which allows increased drug concentration in target tissues while decreasing systemic toxicity.

Label: Liposomal Eribulin Mesylate

NCI Thesaurus Code: C111899 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL454231  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
E7389 Liposomal Formulation
Liposomal Eribulin Mesylate

External Source Codes: 
PDQ Closed Trial Search ID 753504
PDQ Open Trial Search ID 753504 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C111899
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom